Stereotactic radiotherapy for wet age-related macular degeneration: Current perspectives

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 1829-1834

  Neffendorf, James E ^a   Jackson, Timothy L ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Radiation therapy; Stereotactic radiotherapy; Vascular endothelial growth factor; Wet age related macular degeneration

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

AGE RELATED MACULAR DEGENERATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLINDNESS; BRACHYTHERAPY; BRACHYTHERAPY DEVICE; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; EPIMACULAR BRACHYTHERAPY; HUMAN; IONIZING RADIATION; MAJOR CLINICAL STUDY; OUTPATIENT CARE; RANDOMIZED CONTROLLED TRIAL; RETINA; SCLERA; STEREOTACTIC TREATMENT; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VITRECTOMY;

EID: 84942880203     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S75638     Document Type: Article

References (38)

1. Congdon N, O’Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004; 122(4):477–485.
2. Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol. 2004; 11(2):67–115.
3. Macularsociety.org [homepage on the Internet]. The Macular Society, United Kingdom; 2013. Available from: www.macularsociety.org. Accessed July 15, 2013.
4. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet. 2007; 370(9583):204–206.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419–1431.
6. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1432–1444.
7. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364(20):1897–1908.
8. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012; 119(7):1388–1398.
9. Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013; 27(7):787–794.
10. Kirwan JF, Constable PH, Murdoch IE, Khaw PT. Beta irradiation: new uses for an old treatment: a review. Eye (Lond). 2003; 17(2):207–215.
11. Barnhard HJ. Supervoltage therapy comes of age. N Engl J Med. 1958; 258(6):275–277.
12. Paulson DF. Carcinoma of the prostate: the therapeutic dilemma. Annu Rev Med. 1984; 35:341–372.
13. Lenz M, Freid JR. Metastases to the skeleton, brain and spinal cord from cancer of the breast and the effect of radiotherapy. Ann Surg. 1931; 93(1):278–293.
14. Nevarez JA, Parrish RD 2nd, Heuer DK, Hajek AS, Houdek PV, Mallick KS. The effect of beta irradiation on monkey Tenon’s capsule fibroblasts in tissue culture. Curr Eye Res. 1987; 6(5):719–723.
15. Mead KW. Beta irradiation for recurrent pterygia. Trans Ophthalmol Soc Aust. 1956; 16:101–109.
16. Chakravarthy U, Houston RF, Archer DB. Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study. Br J Ophthalmol. 1993; 77(5):265–273.
17. Reinhold HS, Buisman GH. Radiosensitivity of capillary endothelium. Br J Radiol. 1973; 46(541):54–57.
18. Chakravarthy U, Mackenzie G. External beam radiotherapy in exudative age-related macular degeneration: a pooled analysis of phase I data. Br J Radiol. 2000; 73(867):305–313.
19. Jaakkola A, Heikkonen J, Tommila P, Laatikainen L, Immonen I. Strontium plaque brachytherapy for exudative age-related macular degeneration: three-year results of a randomised study. Ophthalmology. 2005; 112(4):567–573.
20. Evans JR, Sivagnanavel V, Chong V. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2010(5):CD004004.
21. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997; 337(14):956–962.
22. Petrarca R, Jackson TL. Radiation therapy for neovascular age-related macular degeneration. Clin Ophthalmol. 2011; 5:57–63.
23. Dugel PU, Petrarca R, Bennett M, et al. Macular epiretinal brachytheraoy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results. Ophthalmology. 2012; 119(7):1425–1431.
24. Petrarca R, Dugel PU, Nau J, Slakter JS, Jaffe GJ, Jackson TL. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography. Ophthalmology. 2013; 120(2):328–333.
25. Petrarca R, Dugel PU, Bennett M, et al. Macular Epiretinal Brachy-therapy in treated Age-Related Macular Degeneration (MERITAGE): Month 24 Safety and Efficacy Results. Retina. 2014; 34(5):874–879.
26. Dugel PU, Bebchuk JD, Nau J, et al. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology. 2013; 120(2):317–327.
27. Jackson TL, Dugel PU, Bebchuk JD, et al. Epimacular Brachytherapy for Neovascular Age-Related Macular Degeneration (CABERNET): Fluoroscein Angiography and Optical Coherence Tomography. Ophthalmology. 2013; 120(8):1597–1603.
28. Casaroli-Marano RP, Alforja S, Giralt J, Farah ME. Epimacular brachytherapy for wet AMD: current perspectives. Clin Ophthalmol. 2014; 8:1661–1670.
29. Beer PM, Bakri RJ, Singh RK, Liu W, Peters GB 3rd, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003; 110(4):681–686.
30. Petrarca R, Richardson M, Douiri A, et al. Safety testing of epimacular brachytherapy with microperimetry and indocyanine green angiography: 12-Month Results. Retina. 2013; 33(6):1232–1240.
31. Hanlon J, Lee C, Chell E, et al. Kilovoltage stereotactic radiosurgery for age-related macular degeneration: assessment of optic nerve dose and patient effective dose. Med Phys. 2009; 36(8):3671–3681.
32. Moshfeghi DM, Kaiser PK, Gertner M. Stereotactic low-voltage x-ray irradiation for age-related macular degeneration. Br J Ophthalmol. 2011; 95(2):185–188.
33. Orayainc.com [homepage on the Internet]. USA: Oraya Therapeutics, Inc.; 2014. Available from: http://www.orayainc.com. Accessed December 6, 2014.
34. Canton VM, Quiroz-Mercado H, Velez-Montoya R, et al. 16 Gy low-voltage x-ray irradiation with ranibizumab therapy for AMD: 6-month safety and functional outcomes. Ophthalmic Surg Lasers Imaging. 2011; 42(6):468–473.
35. Canton VM, Quiroz-Mercado H, Velez-Montoya R, et al. 24-Gy low-voltage x-ray irradiation with ranibizumab therapy for neovascular AMD: 6-month safety and functional outcomes. Ophthalmic Surg Lasers Imaging. 2012; 43(1):20–24.
36. Jackson TL, Chakravarthy U, Kaiser PK, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. Ophthalmology. 2013; 120(9):1893–1900.
37. Jackson TL, Chakravarthy U, Slakter JS, et al. Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration: Year 2 Results of the INTREPID Study. Ophthalmology. 2015; 122(1):138–145.
38. Jackson TL, Shusterman EM, Arnoldussen M, Chell E, Wang K, Moshfeghi DM. Stereotactic Radiotherapy for wet age-related macular degeneration (INTREPID): Influence of baseline characteristics on clinical response. Retina (Philadelphia, Pa.). 2015; 35(2):194–204.